InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,475.09
(
0.27%
)
US TECH 100
19,250.80
(
0.45%
)
Dow Jones
39,169.52
(
0.13%
)
Brent Oil
86.67
(
0.16%
)
Bitcoin
62,933.66
(
0.13%
)
Post# of 13742
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

JediMozart

Send PM Follow Ignore
Followers 8
Posts 628
Boards Moderated 0
Alias Born 05/26/2021

JediMozart

Member Level

Re: PennyWorld post# 12278

Monday, 05/02/2022 11:57:44 AM

Monday, May 02, 2022 11:57:44 AM

Post# of 13742
https://finance.yahoo.com/news/medolife-rx-launches-pharmacokinetic-study-110000337.html

“ launched a pharmacokinetic (PK) study on its lead drug candidate Escozine®. The study aims to provide the basis for determining the drug’s exposures in the body. This is part of the latest round of information requested by the United States Food and Drug Administration (FDA) for its Pre-Investigational New Drug (PIND #150335) filing on Escozine® as a potential therapeutic for the SARS-CoV-2 (COVID-19) virus.”
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up